BON Announces $18 Million Cooperation Agreement for Innovative Second-Generation Apple Series Health Products
Bon Natural Life (NASDAQ: BON) has secured an $18 million cooperation agreement with Beijing Huahai Keyuan Technology for the distribution of its second-generation Apple Series health products in Greater China. The 24-month non-exclusive agreement focuses on weight management and metabolic health products.
The company's innovative formulation combines apple polyphenols with plant protein, achieving 80% higher bioactivity than its first generation through advanced low-temperature extraction technology. Market validation shows similar apple polyphenol blends generating over $40 million in monthly sales.
The second-generation products offer benefits including improved lipid metabolism, enhanced body composition, and reduced age-related muscle loss, positioning BON strategically in the growing nutraceutical market.
Bon Natural Life (NASDAQ: BON) ha siglato un accordo di cooperazione da 18 milioni di dollari con Beijing Huahai Keyuan Technology per la distribuzione dei suoi prodotti salutistici di seconda generazione della serie Apple nella Grande Cina. L'accordo non esclusivo della durata di 24 mesi è incentrato su prodotti per la gestione del peso e la salute metabolica.
La formulazione innovativa dell'azienda combina polifenoli di mela con proteine vegetali, raggiungendo una bioattività superiore dell'80% rispetto alla prima generazione grazie a una tecnologia avanzata di estrazione a bassa temperatura. La validazione di mercato mostra blend simili di polifenoli di mela che generano oltre 40 milioni di dollari di vendite mensili.
I prodotti di seconda generazione offrono benefici come il miglioramento del metabolismo lipidico, una composizione corporea ottimizzata e una riduzione della perdita muscolare legata all'età, posizionando BON in modo strategico nel mercato nutraceutico in crescita.
Bon Natural Life (NASDAQ: BON) ha asegurado un acuerdo de cooperación de 18 millones de dólares con Beijing Huahai Keyuan Technology para la distribución de sus productos de salud de segunda generación de la serie Apple en la Gran China. El acuerdo no exclusivo de 24 meses se centra en productos para el control de peso y la salud metabólica.
La formulación innovadora de la compañía combina polifenoles de manzana con proteína vegetal, logrando una bioactividad un 80% mayor que la de la primera generación gracias a una avanzada tecnología de extracción a baja temperatura. La validación del mercado muestra mezclas similares de polifenoles de manzana que generan más de 40 millones de dólares en ventas mensuales.
Los productos de segunda generación ofrecen beneficios como la mejora del metabolismo de lípidos, una mejor composición corporal y la reducción de la pérdida muscular relacionada con la edad, posicionando a BON estratégicamente en el creciente mercado nutracéutico.
Bon Natural Life (NASDAQ: BON)는 베이징 후아하이 커위안 테크놀로지(Beijing Huahai Keyuan Technology)와 1,800만 달러 규모의 협력 계약을 체결하여 그레이터 차이나 지역에 자사 2세대 Apple 시리즈 건강 제품을 유통합니다. 이 24개월 비독점 계약은 체중 관리 및 대사 건강 제품에 중점을 둡니다.
회사의 혁신적 제형은 사과 폴리페놀과 식물성 단백질을 결합하여 저온 추출 기술을 통해 1세대보다 80% 높은 생체활성을 달성합니다. 시장 검증 결과 유사한 사과 폴리페놀 혼합물이 월 4,000만 달러 이상의 매출을 기록하고 있습니다.
2세대 제품은 지질 대사 개선, 체성분 향상, 연령 관련 근육 손실 감소 등의 이점을 제공하여 성장하는 뉴트라슈티컬 시장에서 BON의 전략적 입지를 강화합니다.
Bon Natural Life (NASDAQ: BON) a conclu un accord de coopération de 18 millions de dollars avec Beijing Huahai Keyuan Technology pour la distribution de ses produits santé de seconde génération de la série Apple dans la Grande Chine. L'accord non exclusif de 24 mois porte sur des produits de gestion du poids et de santé métabolique.
La formulation innovante de la société combine polyphénols de pomme et protéines végétales, atteignant une bioactivité supérieure de 80% par rapport à la première génération grâce à une technologie avancée d'extraction à basse température. La validation du marché montre que des mélanges similaires de polyphénols de pomme génèrent plus de 40 millions de dollars de ventes mensuelles.
Les produits de seconde génération offrent des bénéfices tels qu'une amélioration du métabolisme lipidique, une composition corporelle optimisée et une réduction de la perte musculaire liée à l'âge, positionnant BON de manière stratégique sur le marché nutraceutique en croissance.
Bon Natural Life (NASDAQ: BON) hat eine 18-Millionen-Dollar-Kooperationsvereinbarung mit Beijing Huahai Keyuan Technology abgeschlossen, um seine zweite Generation der Apple Series Gesundheitsprodukte in Greater China zu vertreiben. Die 24-monatige nicht-exklusive Vereinbarung konzentriert sich auf Gewichtsmanagement- und metabolische Gesundheitsprodukte.
Die innovative Formel des Unternehmens kombiniert Apfelpolyphenole mit Pflanzenprotein und erreicht durch fortschrittliche Niedrigtemperatur-Extraktionstechnologie eine 80% höhere Bioaktivität als die erste Generation. Die Marktbewährung zeigt, dass ähnliche Apfelpolyphenol-Mischungen über 40 Millionen Dollar Monatsumsatz erzielen.
Die Produkte der zweiten Generation bieten Vorteile wie verbesserte Lipidstoffwechsel, bessere Körperzusammensetzung und verringerte altersbedingte Muskelverluste, wodurch BON strategisch im wachsenden Nutraceutical-Markt positioniert ist.
- Secured $18 million distribution agreement for 24 months
- Second-generation product achieves 80% higher bioactivity than predecessor
- Similar products generate over $40 million in monthly sales
- Vertically integrated supply chain from raw materials to production
- Enhanced formulation expected to drive significant revenue and profit growth
- Non-exclusive distribution agreement may limit market control
- Agreement limited to Greater China market only
Insights
BON secures $18M distribution deal for enhanced apple polyphenol products with significant revenue potential in China's growing metabolic health market.
BON Natural Life has strategically positioned itself in the high-growth metabolic health and weight management sectors with this
The technical innovation here is substantial. BON's second-generation Apple Series products utilize advanced low-temperature extraction technology that delivers
The company's vertical integration from raw materials through production provides significant margin protection and supply chain control - critical factors for maintaining product quality and profitability in the premium nutraceutical segment. This vertically integrated approach typically translates to stronger gross margins and better quality control than competitors relying on third-party manufacturing.
Market timing appears favorable as protein supplements have evolved from niche products to mainstream health essentials. BON's strategic combination of apple polyphenols with plant protein addresses multiple consumer demands simultaneously: weight management, metabolic health, and protein supplementation. This multi-benefit positioning aligns with current consumer preferences for products offering multiple functional benefits in a single solution.
While the
Leveraging advanced low-temperature extraction technology, BON's second-generation Apple Series delivers
After decades of evolution, protein supplements have become mainstream health essentials, integral to fitness regimens, immune support programs, and longevity-focused nutrition plans. BON's innovative incorporation of apple polyphenols into protein supplements delivers clinically validated benefits, including improved lipid metabolism, enhanced body composition, and reduced of age-related muscle loss - positioning the product at the intersection of established market needs and innovative functionality with significant growth potential.
Early market validation is encouraging, with comparable apple polyphenol blends generating over
"We have both the responsibility and capability as a global leader in apple polyphenols to develop superior health solutions," stated Mr. Yongwei Hu, Chairman and CEO of BON. "Through our vertically integrated supply chain - from raw materials to production - we are well-positioned to lead the rapidly growing metabolic health segment. The enhanced bioactivity of our second-generation apple polyphenols is expected to drive significant revenue and profit growth across nutraceutical and functional food markets, enhancing shareholder value and delivering strong returns."
About Bon Natural Life Limited ("BON")
BON is a
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
View original content:https://www.prnewswire.com/news-releases/bon-announces-18-million-cooperation-agreement-for-innovative-second-generation-apple-series-health-products-302550246.html
SOURCE Bon Natural Life Limited
FAQ
What is the value and duration of BON's new distribution agreement?
How does BON's second-generation Apple Series product improve upon the first generation?
What are the key benefits of BON's Apple Series health products?
What is the market potential for BON's apple polyphenol products?
How will the new agreement affect BON's market presence?
